Skip to main content
Premium Trial:

Request an Annual Quote

HalioDx Closes €18.5M Series B Round

NEW YORK (GenomeWeb) – French immuno-oncology diagnostics firm HalioDx announced today that it has closed an €18.5 million ($22.7 million) Series B financing round.

Investors in the financing— which follows a €7.5 million Series A round at the time of the company's formation in March 2015 — included Bpifrance, Capricorn Venture Partners, and Amundi Private Equity Funds, as well as existing investors MI Care, Sham Innovation Santé/Turenne, BNP Paribas Development, and Sofipaca.

HalioDx said that the new investment would be used to continue development of its CE-IVD marked Immunoscore colon cancer assay — which measures the density of two T lymphocyte populations to help physicians assess disease prognosis — and to advance Immunoscore assays in additional cancer types. The company also plans to establish commercial operations in the US.

"This Series B financing will enable us to execute our plans faster and enter efficiently the US market," HalioDx CEO Vincent Fert said in a statement. "I am looking forward to see Immunoscore ... in oncologists' routine practice to manage prescriptions across multiple cancer indications."

The Scan

Time to Act

A new report urges the UK to consider regulations to protect against the misuse of genomic technologies, according to the Guardian.

Fulgent Seeking Defamation Suit

Fulgent Genetics says it plans to sue Los Angeles County Sheriff Alex Villanueva for defamation, the Los Angeles Times reports.

Speeding Gene-Edited Crops

Reuters reports that China's new trial rules will make it easier to grow gene-edited crops there.

Nucleic Acids Research Papers on Viral Recombination, Pan-Cancer Mutations, SARS-CoV-2 Variability

In Nucleic Acids Research this week: updated pipeline to detect viral recombination, mutational patterns in tumor samples, and more.